▼Romosozumab for osteoporosis

2021 ◽  
pp. dtb-2021-000027
Keyword(s):  
High Risk ◽  
Postmenopausal Women ◽  
Brand Name ◽  
Market Authorisation ◽  
Antiresorptive Therapy ◽  
Severe Osteoporosis ◽  
Subcutaneous Injections ◽  
Risk Of Fracture ◽  
Authorisation Holder ◽  
Additional Monitoring

AbstractGeneric name: RomosozumabBrand name: EvenityFormulation: 105 mg solution for injection in a pre-filled penMarket Authorisation holder: UCB Pharma LimitedIndication: treatment of severe osteoporosis in postmenopausal women at high risk of fractureDose: 210 mg romosozumab (administered as two subcutaneous injections of 105 mg each) once a month for 12 months. It is recommended that patients begin antiresorptive therapy after completing treatment with romosozumab.Cost: £427.75 for two pre-filled pens each containing 105 mg romosozumabClassification: Prescription only medicine (POM) subject to additional monitoring (▼)

Esketamine for treatment-resistant depression

2020 ◽  
Vol 58 (12) ◽  
pp. 183-188
Keyword(s):  
Reuptake Inhibitor ◽  
Brand Name ◽  
Treatment Resistant ◽  
Major Depressive ◽  
Spray Solution ◽  
Noradrenaline Reuptake ◽  
Starting Dose ◽  
Resistant Depression ◽  
Authorisation Holder ◽  
Additional Monitoring

Generic name: Esketamine hydrochlorideBrand name: SpravatoFormulation: 28mg in 0.2ml nasal spray solutionMarket Authorisation holder: Janssen-Cilag International NVIndication: Treatment resistant major depressive disorder in adults who have failed to respond to at least two different antidepressants during the current moderate to severe episode. To be used in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI).Dose: The starting dose is 56 mg for adults aged <65 years and 28 mg for adults aged ≥65 years 1 . Subsequent doses (56 mg or 84 mg for those <65 years; 28 mg, 56 mg or 84 mg for those ≥65 years) are given twice a week for 4 weeks, followed by once a week for 4 weeks, and then once a week or once every 2 weeks from week 9. Treatment is recommended for at least 6 months after symptoms improve.Cost: £163 for 28 mg (one device)Classification: Prescription only medicine (POM) subject to additional monitoring (▼). Controlled drug schedule 2.

Identifying Postmenopausal Women at High Risk of Fracture in Populations: A Comparison of Three Strategies

2002 ◽  
Vol 50 (6) ◽  
pp. 1031-1038 ◽  
Author(s):  
Diana S.M. Buist ◽  
Andrea Z. LaCroix ◽  
David Manfredonia ◽  
Thomas Abbott
Keyword(s):  
High Risk ◽  
Postmenopausal Women ◽  
Risk Of Fracture

Osteoporosis Therapy in Postmenopausal Women With High Risk of Fracture

JAMA ◽  
2016 ◽  
Vol 316 (7) ◽  
pp. 715 ◽  
Author(s):  
Anne R. Cappola ◽  
Dolores M. Shoback
Keyword(s):  
High Risk ◽  
Postmenopausal Women ◽  
Osteoporosis Therapy ◽  
Risk Of Fracture

scholarly journals High-risk HPV genotypes and cervical lesions association in postmenopausal women

2021 ◽  
Vol 31 (Supplement_2) ◽  
Author(s):  
Ana Rita Fernandes Miranda da Costa ◽  
Cláudia Sousa ◽  
Erica Isidoro ◽  
Regina Silva ◽  
Cristiana Mourato
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Postmenopausal Women ◽  
Age Groups ◽  
Low Grade ◽  
High Grade ◽  
Cervical Lesions ◽  
Intraepithelial Lesion ◽  
The Bethesda System ◽  
High Risk Hpv

Abstract Background Persistent infection by high-risk Human Papillomavirus (hrHPV) are the major cause of cervical cancer. Studies report disparities in the incidence of infection and the various genotypes of this virus in different age groups, suggesting a higher frequency of hrHPV in young women and low-risk subtypes being predominant in older women. This study aimed to investigate the incidence and distribution of hrHPV genotypes in postmenopausal women as well as the correlation with the cytological findings. Methods 16 859 women, aged 50–64 years, performed cervical cancer screening test in Friuri Venezia Giulia region, Italy. The infection was evaluated by the Polymerase Chain Reaction methodology and the positive samples were evaluated by Liquid Based Cytology according to the Bethesda System from 2014. A statistical analysis was performed to study the molecular and cytological data of this population. Results hrHPV infection were found in 5.8% of the women and 78.3% of these were caused by hrHPV other than HPV16 and HPV18 (). Also, 65.7% of the positive samples were negative for intraepithelial lesion or malignancy while low grade squamous intraepithelial lesion was the most frequent (22.4%). There was an increase in the number of high-grade intraepithelial lesions in the presence of HPV16 compared to that recorded when this genotype was absent (20.8% vs. 8.5%). No cervical cancers were detected. Conclusions Infection with hrHPV is uncommon in postmenopausal women and it is mostly caused by subtypes less associated with the development of cervical cancer. Yet, HPV16 infection triggers the development of high-grade lesions.

scholarly journals ANABOLIChESKAYa TERAPIYa OSTEOPOROZA.TERIPAPARATID: EFFEKTIVNOST', BEZOPASNOST' I OBLAST' PRIMENENIYa

2013 ◽  
Vol 16 (2) ◽  
pp. 32-40
Author(s):  
Zh E BELAYa ◽  
L Ya ROZhINSKAYa
Keyword(s):  
Bone Formation ◽  
Bone Remodeling ◽  
Vertebral Fractures ◽  
Previous Treatment ◽  
Fragility Fractures ◽  
Bone Modeling ◽  
Severe Osteoporosis ◽  
Subcutaneous Injections ◽  
Acid Fragment ◽  
History Of

This review of the literature has been dedicated to experimental and clinical studies of mechanism of action and efficacy of 1—34 amino acid fragment of parathyroid hormone — teriparatide as well as others contries experience of its prescribtion. Teriparatide is an osteoanabolic agent which stimulates bone formation by affecting bone modeling and by stimulating bone remodeling. The effects on modeling lead to increased bone formation whereas the effects on bone remodeling lead to increased bone turnover. Thus, in its mode of action teriparatide differs from all others medicines currently available to treat osteoporosis. Daily subcutaneous injections of teriparatide are proved to be effective to prevent low-traumatic vertebral and non-vertebral fractures in postmenopausal women with the history of vertebral fractures. Teriparatide is effective to treat osteoporosis in male and even more effective than alendronate to treat glucocorticoid-induced osteoporosis. Due to high cost and some restriction related to the duration of therapy (up to 18 months in Russia and 24 months in others countries) teriparatide should be recommended to treat severe osteoporosis in patients with a history >1 moderate clinical vertebral fracture or two or more vertebral fragility fractures or in case the previous treatment was not effective. Teriparatide should be prescribed after bisphosphonates or other antiosteoporotic treatment, but not in the combination with bisphosphonates. The prescribtion of bisphosphonates after teriparatide is effective to maintaine and further improve the effect. Thus, teriparatide is effective to treat severe osteoporosis and osteoporosis resistant to other therapy.

scholarly journals Human papillomavirus infection rate, distribution characteristics, and risk of age in pre- and postmenopausal women

2020 ◽  
Author(s):  
Yan Shen ◽  
Jing Xia ◽  
Hui hui Li ◽  
Yang Xu ◽  
San ping Xu
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Postmenopausal Women ◽  
Infection Rate ◽  
Genital Tract ◽  
Hpv Infection ◽  
Distribution Characteristics ◽  
Lower Genital Tract ◽  
Significant Difference ◽  
High Risk Hpv

Abstract BackgroundThe incidence rate of cervical cancer is increasing yearly. The persistent infection of high-risk Human Papillomavirus (HPV) is the main factor leading to cervical cancer. HPV infection is double peak type. This study aimed at analyzing the HPV distribution characteristics, infection rate, and risk of age in pre- and postmenopausal women. So as to provide reference for the prevention of HPV infection and cervical cancer screening strategy.MethodsA retrospective analysis of 4614 women who underwent cervical cytology, and HPV examination from January 2018 to October 2019 at the healthcare department of Wuhan Union Hospital was done. We explored the characteristics and distribution of HPV infections around the menopause, then comparing the infection rate of HPV in postmenopause and over 65 years old, in order to analyze the influence of different ages on HPV infection.ResultsGenerally, the HPV infection rate was 13.10% (539 / 4115), whereby the high-risk subtype constituted 73.84% (398 / 539) of all positive cases. On the other hand, the HPV39 infection was more common in postmenopausal women; however, there was no significant difference in the distribution of the other types in the pre- and postmenopausal women (Insert p value). The first four subtypes were 52 / 53 / 58 / 16, respectively. The infection rate of HPV in patients with lower genital tract inflammation was significantly higher, P = 0.000, 95% CI: 1.911 (1.416, 2.580) compared with those without lower genital tract inflammation. The results further showed that there was no significant difference between pre- and postmenopausal women in terms of HPV infection rate, but more susceptible to high-risk HPV infection after the age of 65 (P = 0.041). Except for 40 years old to menopause, the infection rate of high-risk HPV in this age group was different from that in postmenopause(P = 0.023,0.729(0.555,0.957)), other age groups had no significant effect on high-risk HPV infection.ConclusionsIt was concluded that whether menopause has nothing to do with HPV infection. Moreover, the infection rate of high-risk HPV increases after 65 years of age; hence the cutoff screening age should be appropriately prolonged.Trial registration: Retrospectively registered.

Sign in / Sign up

Export Citation Format

Share Document